Bristol-Myers Squibb‘s oncology business accounts for over 60% of the company valuation, according to our estimates. The performance of pharmaceutical stocks is highly tied to clinical trial results, and for BMY the uptake of its new cancer drugs, especially Opdivo, is of key importance.
from Forbes Real Time https://www.forbes.com/sites/greatspeculations/2017/09/18/opdivo-in-focus-after-bmys-checkmate-214-study-being-stopped-early/
via IFTTT
No comments:
Post a Comment